Cancer and Immunotherapy · global
Selectively Activating T Cells: New Antibody Shows Signs of Efficacy in a Trial of Refractory Solid Tumors
Invikafusp alfa targets two T-cell populations, with 4 of 27 patients in selected dose groups achieving an objective response. This early study offers new clues for addressing treatment challenges after immunotherapy failure, but larger trials are still needed to determine how to identify patients who may benefit and how long the effects may last.
When cancer repeatedly breaks through multiple lines of treatment, restoring the immune system’s ability to act becomes a shared challenge for patients and researchers. The experimental antibody invikafusp alfa (invika for short) is testing a more selective approach: focusing activation on specific T cells. Results from a first-in-human trial published in Nature Medicine on October 23 showed tumor shrinkage in some patients with solid tumors who had received multiple lines of treatment, including cancer types that have traditionally been difficult to treat with immunotherapy.
According to an announcement from Canada’s University Health Network (UHN), the phase 1/2 study, called START-001, treated 58 people at 10 cancer centers across four countries; the main analysis reported here covered 52 of them, representing 21 types of solid tumors. The paper used data collected through March 12, 2025, including 34 phase 1 participants and 18 early phase 2 participants. More than half of the patients had previously received at least four lines of treatment, and most had received immune checkpoint inhibitors.
Invika is a bispecific antibody that targets T cells bearing Vβ6 or Vβ10 receptor features in patients’ bodies. The study’s premise is that selectively stimulating these two cell populations could focus the antitumor immune response while limiting unnecessary stimulation of other immune cells. The research team did observe expansion of the target T-cell populations in blood and tumors, providing preliminary evidence that the drug acts as intended; however, an increase in immune cells does not guarantee tumor shrinkage.
Among 27 people who received 0.08 or 0.12 milligrams per kilogram of body weight, which the researchers designated as optimal biological doses, 4 achieved an objective response, a rate of 14.8%. Responses occurred in cases including microsatellite-stable colorectal cancer and PD-L1-negative non-small cell lung cancer. These results suggest that selective T-cell activation may have an effect in some refractory tumors, but the number of patients remains insufficient to estimate efficacy for individual cancer types.
The efficacy figures also require careful distinction. UHN noted that 44.4% of patients in the same 27-person dose group experienced some degree of tumor shrinkage, but only 4 met the threshold for an objective response. Separately, among 18 patients whose previous immunotherapy had failed, 66.7% achieved disease control, meaning their tumors shrank or remained stable. Stable disease has clinical significance, but it cannot be directly interpreted as tumor regression, nor does it yet answer whether survival can be extended.
Regarding safety, the most common treatment-related adverse event was cytokine release syndrome, predominantly grade 1 or 2. There were two reversible dose-limiting toxicities in the trial, with no treatment-related deaths reported and no grade 4 non-laboratory adverse events. Based on the combined safety, pharmacokinetic, and immune response data, the researchers selected 0.08 milligrams per kilogram as the recommended phase 2 dose.
The clearest progress so far is that the study has identified a dose for further testing and observed antitumor activity in a small number of patients. The small sample size and wide variation in cancer types and treatment histories make it difficult to apply the results directly to individual patients or determine whether the treatment is superior to existing therapies. Sponsored and funded by developer Marengo Therapeutics, with additional partial support from the US National Cancer Institute, the study is continuing its phase 2 evaluation; larger samples and longer follow-up will be needed to clarify who may benefit and how long responses may last.